AMTD Digital Inc Reports 565.7% Revenue Growth in FY25
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 02 2026
0mins
Source: Benzinga
- Significant Revenue Growth: AMTD Digital Inc reported a staggering 565.7% year-over-year increase in FY25 revenue, reaching $136.1 million, which significantly enhances the company's financial performance and indicates strong market demand for its services.
- Stock Price Surge: Following the positive earnings report, AMTD Digital's shares jumped 24.4% to $2.18 in pre-market trading, reflecting investor optimism regarding the company's future growth potential and profitability.
- Positive Market Reaction: The robust financial results have garnered widespread attention in the market, potentially attracting more investors and further driving up the stock price while bolstering overall market confidence in the company.
- Strategic Implications: The revenue growth not only strengthens AMTD Digital's market position but also provides financial resources for future expansion and investments, enhancing its competitiveness in the digital finance sector.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AARD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AARD
Wall Street analysts forecast AARD stock price to rise
10 Analyst Rating
10 Buy
0 Hold
0 Sell
Strong Buy
Current: 3.820
Low
18.00
Averages
33.00
High
50.00
Current: 3.820
Low
18.00
Averages
33.00
High
50.00
About AARD
Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. The Company targets biological pathways associated with alleviating hunger that has the potential to deliver transformative outcomes for patients. It is focused on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its initial compounds target TAS2Rs expressed in the gut lumen, which normally respond to the nutrients in food and participate in the gut-brain axis. Its wholly owned lead product candidate, ARD-101 (denatonium acetate monohydrate), is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which it has initiated a Phase III clinical trial for hyperphagia associated with Prader-Willi Syndrome (PWS).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aardvark Therapeutics Faces Investigation After Trial Halt
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, the suspension of its HERO trial, resulting in a 56% drop in share price, raising investor concerns about the company's transparency and potentially affecting future financing capabilities.
- Safety Risk Disclosure: The company stated that the trial was paused due to serious safety risks, specifically 'reversible cardiac observations,' leading to significant investor anxiety regarding the safety of ARD-101, which may result in a trust crisis.
- Legal Investigation Initiated: Hagens Berman has launched an investigation into Aardvark, focusing on whether the company misled investors regarding safety and efficacy data, which could lead to legal liabilities and further damage the company's reputation.
- Severe Market Reaction: The emergence of cardiac safety signals prompted analysts to swiftly reduce or suspend their price targets for Aardvark, reflecting a pessimistic outlook on the company's future and potentially leading to a further decline in investor confidence.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56%
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, that it was halting the HERO trial, resulting in a $7.02 (56%) drop in share price, a significant decision driven by concerns over safety risks associated with ARD-101, directly impacting investor confidence and market performance.
- Investor Investigation Launched: Hagens Berman law firm has initiated an investigation into Aardvark for potentially misleading investors regarding the safety and efficacy data of ARD-101, which could lead to further losses for investors.
- FDA Communication Issues: Aardvark previously claimed ARD-101 was a
See More
Aardvark Therapeutics Shares Plunge 56% After Trial Halt
- Trial Suspension: On March 2, 2026, Aardvark Therapeutics announced the halt of its HERO trial for ARD-101 in patients with Prader-Willi Syndrome, resulting in a staggering $7.02 (56%) drop in share price, a decision driven by serious safety risks that undermined investor confidence.
- Investor Investigation Launched: Hagens Berman has initiated an investigation into Aardvark for potentially misleading investors regarding the safety and efficacy of ARD-101, raising concerns about possible violations of federal securities laws and exacerbating market anxiety.
- FDA Communication Issues: Aardvark previously touted ARD-101 as a “first-in-class” drug and claimed alignment with the FDA; however, the trial suspension has led to skepticism about the transparency of its communications with the FDA, prompting analysts to sharply reduce or suspend their price targets.
- Potential Legal Consequences: Investors who suffered significant losses due to Aardvark's disclosures are encouraged to report their losses, as they may face risks of collective lawsuits, further impacting the company's reputation and future financing capabilities.
See More
Aardvark Therapeutics Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Aardvark Therapeutics, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in a healthy volunteer study, resulting in a 56.2% stock price drop to $5.47 per share on March 2.
- FDA Clinical Hold: On May 14, 2026, Aardvark revealed that the FDA imposed a full clinical hold on its investigational new drug application, affecting all ongoing studies, including the HERO trial, causing a further 32.1% decline in stock price to $4.57 per share on May 15.
- Investor Advisory: Investors are advised to contact Pomerantz LLP for information on joining the class action lawsuit, indicating that the company's legal and regulatory challenges may severely impact its future financial performance.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plummet
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, that it would halt the HERO trial, resulting in a 56% drop in share price, equating to a $7.02 loss per share, which severely undermines investor confidence and may affect future financing capabilities.
- Safety Risk Disclosure: The company cited “reversible cardiac observations” as the reason for pausing the trial, contrasting sharply with previous assurances of ARD-101's favorable safety profile, potentially prompting further scrutiny from regulatory bodies.
- Investor Investigation Initiated: Hagens Berman law firm has launched an investigation into whether Aardvark misled investors regarding safety and efficacy disclosures, which could lead to legal liabilities and reputational damage for the company.
- Analyst Target Downgrades: Following the emergence of cardiac safety signals, analysts swiftly reduced or suspended their price targets for Aardvark, exacerbating market uncertainty regarding the company's future prospects.
See More
Aardvark Therapeutics Faces FDA Clinical Hold on ARD-101
- FDA Clinical Hold: Aardvark Therapeutics' IND application for ARD-101 has been placed on full clinical hold by the FDA, resulting in a ~30% drop in stock price during Friday trading, which poses significant challenges for the company's future research endeavors.
- Study Suspension: The phase III HERO study and open-label extension have been halted due to cardiac safety signals observed in healthy volunteers, affecting the treatment progress of 68 participants and potentially delaying critical data collection.
- Strong Cash Position: As of February 27, the company reported sufficient cash, cash equivalents, and short-term investments to sustain operations through mid-2027, despite the significant challenges posed by the clinical hold.
- Data Unblinding Plan: Aardvark plans to unblind the data collected from both the HERO and OLE trials, aiming to assess the efficacy and safety of the existing data to inform future research directions.
See More
Aardvark Therapeutics Faces Investigation After Trial Halt
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, the suspension of its HERO trial, resulting in a 56% drop in share price, raising investor concerns about the company's transparency and potentially affecting future financing capabilities.
- Safety Risk Disclosure: The company stated that the trial was paused due to serious safety risks, specifically 'reversible cardiac observations,' leading to significant investor anxiety regarding the safety of ARD-101, which may result in a trust crisis.
- Legal Investigation Initiated: Hagens Berman has launched an investigation into Aardvark, focusing on whether the company misled investors regarding safety and efficacy data, which could lead to legal liabilities and further damage the company's reputation.
- Severe Market Reaction: The emergence of cardiac safety signals prompted analysts to swiftly reduce or suspend their price targets for Aardvark, reflecting a pessimistic outlook on the company's future and potentially leading to a further decline in investor confidence.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plunge 56%
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, that it was halting the HERO trial, resulting in a $7.02 (56%) drop in share price, a significant decision driven by concerns over safety risks associated with ARD-101, directly impacting investor confidence and market performance.
- Investor Investigation Launched: Hagens Berman law firm has initiated an investigation into Aardvark for potentially misleading investors regarding the safety and efficacy data of ARD-101, which could lead to further losses for investors.
- FDA Communication Issues: Aardvark previously claimed ARD-101 was a
See More
Aardvark Therapeutics Shares Plunge 56% After Trial Halt
- Trial Suspension: On March 2, 2026, Aardvark Therapeutics announced the halt of its HERO trial for ARD-101 in patients with Prader-Willi Syndrome, resulting in a staggering $7.02 (56%) drop in share price, a decision driven by serious safety risks that undermined investor confidence.
- Investor Investigation Launched: Hagens Berman has initiated an investigation into Aardvark for potentially misleading investors regarding the safety and efficacy of ARD-101, raising concerns about possible violations of federal securities laws and exacerbating market anxiety.
- FDA Communication Issues: Aardvark previously touted ARD-101 as a “first-in-class” drug and claimed alignment with the FDA; however, the trial suspension has led to skepticism about the transparency of its communications with the FDA, prompting analysts to sharply reduce or suspend their price targets.
- Potential Legal Consequences: Investors who suffered significant losses due to Aardvark's disclosures are encouraged to report their losses, as they may face risks of collective lawsuits, further impacting the company's reputation and future financing capabilities.
See More
Aardvark Therapeutics Faces Securities Fraud Investigation
- Securities Fraud Investigation: Pomerantz LLP is investigating claims against Aardvark Therapeutics, Inc. regarding potential securities fraud by the company and its executives, which could lead to significant investor losses.
- Trial Suspension: On February 27, 2026, Aardvark announced a voluntary pause of its Phase 3 HERO trial due to reversible cardiac observations in a healthy volunteer study, resulting in a 56.2% stock price drop to $5.47 per share on March 2.
- FDA Clinical Hold: On May 14, 2026, Aardvark revealed that the FDA imposed a full clinical hold on its investigational new drug application, affecting all ongoing studies, including the HERO trial, causing a further 32.1% decline in stock price to $4.57 per share on May 15.
- Investor Advisory: Investors are advised to contact Pomerantz LLP for information on joining the class action lawsuit, indicating that the company's legal and regulatory challenges may severely impact its future financial performance.
See More
Aardvark Therapeutics Halts HERO Trial, Shares Plummet
- Trial Suspension Impact: Aardvark Therapeutics announced on March 2, 2026, that it would halt the HERO trial, resulting in a 56% drop in share price, equating to a $7.02 loss per share, which severely undermines investor confidence and may affect future financing capabilities.
- Safety Risk Disclosure: The company cited “reversible cardiac observations” as the reason for pausing the trial, contrasting sharply with previous assurances of ARD-101's favorable safety profile, potentially prompting further scrutiny from regulatory bodies.
- Investor Investigation Initiated: Hagens Berman law firm has launched an investigation into whether Aardvark misled investors regarding safety and efficacy disclosures, which could lead to legal liabilities and reputational damage for the company.
- Analyst Target Downgrades: Following the emergence of cardiac safety signals, analysts swiftly reduced or suspended their price targets for Aardvark, exacerbating market uncertainty regarding the company's future prospects.
See More
Aardvark Therapeutics Faces FDA Clinical Hold on ARD-101
- FDA Clinical Hold: Aardvark Therapeutics' IND application for ARD-101 has been placed on full clinical hold by the FDA, resulting in a ~30% drop in stock price during Friday trading, which poses significant challenges for the company's future research endeavors.
- Study Suspension: The phase III HERO study and open-label extension have been halted due to cardiac safety signals observed in healthy volunteers, affecting the treatment progress of 68 participants and potentially delaying critical data collection.
- Strong Cash Position: As of February 27, the company reported sufficient cash, cash equivalents, and short-term investments to sustain operations through mid-2027, despite the significant challenges posed by the clinical hold.
- Data Unblinding Plan: Aardvark plans to unblind the data collected from both the HERO and OLE trials, aiming to assess the efficacy and safety of the existing data to inform future research directions.
See More
